{"favorite_id": 3981, "calc_type": "", "dosing": false, "full_title_en": "Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndrome (MDS)", "short_title_en": "IPSS-R", "medium_description_en": "<span>Stages patients with MDS.</span>", "short_description_en": "MDS staging.", "before_use": "", "instructions_en": "<p>Use at the time of diagnosis, before starting treatment.</p>", "purpose_en": ["Prognosis"], "disease_en": ["Hematologic Malignancy"], "specialty_en": ["Hematology and Oncology"], "chief_complaint_en": ["Bleeding"], "system_en": ["Oncologic", "Hematologic"], "search_abbreviation_en": ["ipss", "mds", "revised ipss"], "slug": "revised-international-prognostic-scoring-system-ipss-r-myelodysplastic-syndrome-mds", "seo": {"meta_description_en": "Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndrome (MDS)", "keywords_en": "MDS, myelodysplastic, WHO MDS staging, MDS stage"}, "content": {"how_to_use": {"use_case_en": "<p><span>Patients newly-diagnosed with myelodysplastic syndrome. </span></p>", "pearls_pitfalls_en": "<ul> <li><span>The IPSS-R categorizes patients into 1 of 5 groups, from very low risk to very high risk, based on risk of mortality and transformation to acute myeloid leukemia (AML). </span></li> <li><span>This score is not dynamic and is meant to be used at the time of diagnosis only. That being said, the score does get higher with disease progression. </span></li> <li><span>The IPSS-R has better discrimination and is more widely used over the original IPSS (see Evidence).</span></li> <li><span>Data are based on untreated patients, represent statistical probabilities, and are not absolute. </span></li> </ul>", "why_use_en": "<p><span>Can help determine whether to treat or observe, and what type of treatment, based on risk score. </span></p>"}, "next_steps": {"advice_en": "", "management_en": "<ul> <li><span>Very low or low risk patients can be observed and given supportive care only with monitoring of blood counts, unless they have another indication for treatment, such as symptomatic cytopenias. If these patients require treatment, they can usually be managed with low-intensity regimens such as growth factors, hypomethylating agents or lenalidomide. </span></li> <li><span>High or very high risk patients will usually require treatment with high-intensity therapies such as chemotherapy and allogeneic transplant. </span></li> <li><span>Intermediate patients can be treated with either low- or high-intensity treatments based on age, performance status and patient preference. </span></li> <li><span>Patients with deletion 5q and up to one other cytogenetic abnormality (as long as it is not del7q) are special cases that are very low risk and respond to lenalidomide. Treatment-related MDS is also a special category that is very high risk. </span></li> </ul>", "critical_actions_en": "<p><span>Treatment decision should be individualized, and since most patients with MDS are older, comorbid conditions should be taken into consideration. An elderly patient with high risk MDS may still be best suited by a hypomethylating agent and/or considered for a reduced intensity allogeneic stem cell transplant. </span></p>"}, "about": {"formula_en": "<p>Addition of the selected points:</p> <div class=\"table-responsive\"> <table class=\"table table-bordered\"> <tbody> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td> <p><strong>Points</strong></p> </td> </tr> <tr> <td rowspan=\"5\"> <p><strong>Cytogenetic group</strong></p> </td> <td> <p>Very good: del(11q) or -Y</p> </td> <td> <p>0</p> </td> </tr> <tr> <td> <p>Good: normal karyotype, del(20q), del(5q), del(12p), or double including del(5q)</p> </td> <td> <p>1</p> </td> </tr> <tr> <td> <p>Intermediate: +8, del(7q), i(17q), +19, or any other single or double independent clone</p> </td> <td> <p>2</p> </td> </tr> <tr> <td> <p>Poor: -7, inv(3)/t(3q)/del(3q), double including -7/del(7q), or complex (3 abnormalities)</p> </td> <td> <p>3</p> </td> </tr> <tr> <td> <p>Very poor: complex &gt;3 abnormalities</p> </td> <td> <p>4</p> </td> </tr> <tr> <td rowspan=\"4\"> <p><strong>Medullary blasts, %</strong></p> </td> <td> <p>\u22642</p> </td> <td> <p>0</p> </td> </tr> <tr> <td> <p>&gt;2 to &lt;5</p> </td> <td> <p>1</p> </td> </tr> <tr> <td> <p>5 to 10</p> </td> <td> <p>2</p> </td> </tr> <tr> <td> <p>&gt;10</p> </td> <td> <p>3</p> </td> </tr> <tr> <td rowspan=\"3\"> <p><strong>Hemoglobin, g/dL (g/L)</strong></p> </td> <td> <p>\u226510 (\u2265100)</p> </td> <td> <p>0</p> </td> </tr> <tr> <td> <p>8 to &lt;10 (80 to &lt;100)</p> </td> <td> <p>1</p> </td> </tr> <tr> <td> <p>&lt;8 (&lt;80)</p> </td> <td> <p>1.5</p> </td> </tr> <tr> <td rowspan=\"3\"> <p><strong>Platelets, \u00d710</strong><sup><strong>3</strong></sup><strong>/\u00b5L or 10</strong><sup><strong>9</strong></sup><strong>/L</strong></p> </td> <td> <p>\u2265100</p> </td> <td> <p>0</p> </td> </tr> <tr> <td> <p>50 to &lt;100</p> </td> <td> <p>0.5</p> </td> </tr> <tr> <td> <p>&lt;50</p> </td> <td> <p>1</p> </td> </tr> <tr> <td rowspan=\"2\"> <p><strong>ANC, \u00d710</strong><sup><strong>3</strong></sup><strong>/\u00b5L or 10</strong><sup><strong>9</strong></sup><strong>/L</strong></p> </td> <td> <p>\u22650.8</p> </td> <td> <p>0</p> </td> </tr> <tr> <td> <p>&lt;0.8</p> </td> <td> <p>0.5</p> </td> </tr> </tbody> </table> </div> <p>&nbsp;</p> <p>Original IPSS, for historical comparison:</p> <div class=\"table-responsive\"> <table class=\"table table-bordered\"> <tbody> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td> <p><strong>Points</strong></p> </td> </tr> <tr> <td rowspan=\"4\"> <p><strong>Bone marrow blasts, %</strong></p> </td> <td> <p>&lt;5</p> </td> <td> <p>0</p> </td> </tr> <tr> <td> <p>5\u201310</p> </td> <td> <p>0.5</p> </td> </tr> <tr> <td> <p>11\u201320</p> </td> <td> <p>1.5</p> </td> </tr> <tr> <td> <p>21\u201330</p> </td> <td> <p>2</p> </td> </tr> <tr> <td rowspan=\"3\"> <p><strong>Karyotype</strong></p> </td> <td> <p>Good: normal, \u2212Y, del(5q), or del(20q)</p> </td> <td> <p>0</p> </td> </tr> <tr> <td> <p>Intermediate: other abnormalities not listed under good or poor</p> </td> <td> <p>0.5</p> </td> </tr> <tr> <td> <p>Poor: complex (\u22653 abnormalities) or chromosome 7 anomalies</p> </td> <td> <p>1</p> </td> </tr> <tr> <td rowspan=\"2\"> <p><strong>Number of cytopenias</strong></p> </td> <td> <p>0\u20131</p> </td> <td> <p>0</p> </td> </tr> <tr> <td> <p>2\u20133</p> </td> <td> <p>0.5</p> </td> </tr> </tbody> </table> </div>", "more_info_en": "<p>Interpretation:</p>\n<div class=\"table-responsive\">\n<table class=\"table table-bordered\">\n<tbody>\n<tr>\n<td>\n<p><strong>IPSS-R</strong></p>\n</td>\n<td>\n<p><strong>Risk group</strong></p>\n</td>\n<td>\n<p><strong>Median survival, years</strong></p>\n</td>\n<td>\n<p><strong>Median time to 25% AML evolution*</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>&le;1.5</p>\n</td>\n<td>\n<p>Very low</p>\n</td>\n<td>\n<p>8.8</p>\n</td>\n<td>\n<p>Not reached</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>&gt;1.5 to 3</p>\n</td>\n<td>\n<p>Low</p>\n</td>\n<td>\n<p>5.3</p>\n</td>\n<td>\n<p>10.8</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>&gt;3 to 4.5</p>\n</td>\n<td>\n<p>Intermediate</p>\n</td>\n<td>\n<p>3</p>\n</td>\n<td>\n<p>3.2</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>&gt;4.5 to 6</p>\n</td>\n<td>\n<p>High</p>\n</td>\n<td>\n<p>1.6</p>\n</td>\n<td>\n<p>1.4</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>&gt;6</p>\n</td>\n<td>\n<p>Very high</p>\n</td>\n<td>\n<p>0.8</p>\n</td>\n<td>\n<p>0.73</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>*<em>Note</em>: Patients who died were censored in the AML evolution analysis, so median time to 25% AML evolution may exceed median survival. Lower risk patients are more likely to die from another comorbidity than from AML.<br />&nbsp;<img src=\"https://cdn-web-img.mdcalc.com/content/ipss.png\" alt=\"\" width=\"100%\" /></p>\n<p>Figure: Kaplan-Meier curve for IPSS-R by risk group, adapted from <a href=\"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425443/\" target=\"_blank\">Greenberg 2012</a>.</p>\n<p>&nbsp;</p>\n<p>Original IPSS risk groups, for historical comparison:&nbsp;</p>\n<div class=\"table-responsive\">\n<table class=\"table table-bordered\">\n<tbody>\n<tr>\n<td>\n<p><strong>Original IPSS</strong></p>\n</td>\n<td>\n<p><strong>Risk group</strong></p>\n</td>\n<td>\n<p><strong>Median survival</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>0</p>\n</td>\n<td>\n<p>Low</p>\n</td>\n<td>\n<p>5.7 years</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>0.5&ndash;1</p>\n</td>\n<td>\n<p>Intermediate 1</p>\n</td>\n<td>\n<p>3.5 years</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>1.5&ndash;2</p>\n</td>\n<td>\n<p>Intermediate 2</p>\n</td>\n<td>\n<p>1.2 years</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>2.5&ndash;3.5</p>\n</td>\n<td>\n<p>High</p>\n</td>\n<td>\n<p>0.4 years</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p>&nbsp;</p>\n</div>", "evidence_based_medicine_en": "<p>The <a href=\"http://www.bloodjournal.org/content/89/6/2079.long?sso-checked=true\" target=\"_blank\">original IPSS</a> analyzed data from 816 untreated MDS patients by multivariate analysis to devise a score that weighted certain cytogenetic abnormalities, percentage of bone marrow blasts and number of cytopenias based on their correlation with outcome. The <a href=\"http://www.bloodjournal.org/content/89/6/2079.long?sso-checked=true\" target=\"_blank\">revised IPSS</a> (IPSS-R) was developed in 7,012 patients and added some additional cytogenetic abnormalities and used specific blood count value ranges in the calculation. The IPSS had four categories, while the IPSS-R has better discrimination with five categories. Both scores have been validated; however, the IPSS-R is more frequently used and is more precise. The <a href=\"http://www.nature.com/leu/journal/vaop/ncurrent/full/leu201555a.html\" target=\"_blank\">validation</a> for the IPSS-R was performed on 200 external patients and outperformed the IPSS. &nbsp;</p>", "references_list": {"Original/Primary Reference": [{"href": "http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425443/", "text": "Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System for Myelodysplastic Syndromes. Blood. 2012;120(12):2454-2465. doi:10.1182/blood-2012-03-420489."}, {"href": "http://www.bloodjournal.org/content/89/6/2079.long?sso-checked=true", "text": "Greenberg P, Cox C, LeBeau MM et. al. International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes. Blood. 1997; 89;6: 2079 - 2088. Erratum in Blood 1998; 91:1100."}, {"href": "https://www.ncbi.nlm.nih.gov/pubmed/17687155", "text": "Malcovati L, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25:3503-3510 "}], "Other References": [{"href": "http://www.nejm.org/doi/full/10.1056/NEJM199905273402107", "text": "Heaney ML, Golde, DW. Medical Progress: Myelodysplasia. NEJM. 1999; 340;21: 1649-1660."}], "Validation": [{"href": "http://www.nature.com/leu/journal/vaop/ncurrent/full/leu201555a.html", "text": "Della Porta MG, et. al. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). Leukemia. 2015 Feb 27. doi: 10.1038/leu.2015.55. [Epub ahead of print]"}], "Clinical Practice Guidelines": [], "Manufacturer Website": [], "Outcomes": []}}, "contributor": {"expert_name": [{"description": "<p>Justin Taylor, MD, is an assistant professor on the Leukemia Service at Memorial Sloan Kettering Cancer Center. He is board certified in internal medicine and medical oncology. He completed his internship and residency at Brigham and Women\u2019s Hospital in Boston. His clinical and research focuses are on the basic biology and translational significance of somatic genetic mutations in hematologic malignancies.</p>", "firstName": "Justin", "img": "https://cdn-web-img.mdcalc.com/people/justin-taylor.jpg", "lastName": "Taylor", "name": "Justin Taylor, MD", "target": "justin-taylor", "signedCOI": true, "hasDisclosure": []}]}, "creator": [{"name": "Dr. Peter Greenberg", "qa_en": "", "creator_info": {"about_en": "<p>Peter Greenberg, MD, is professor emeritus of hematology at Stanford University. He is also director of the Stanford Myelodysplastic Syndrome (MDS) Center, coordinator of the International Working Group for Prognosis in MDS and chair of the National Comprehensive Cancer Network MDS Practice Guidelines Panel. Dr. Greenberg\u2019s research focuses on evaluating molecular and genetic abnormalities in myelodysplastic syndromes.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-peter-greenberg.jpeg", "pubmedLink": "http://www.ncbi.nlm.nih.gov/pubmed/?term=Greenberg+P%5BAuthor%5D"}}], "reviewer": {"expert_name": [{"name": "Eytan Stein, MD"}]}, "related_resources": {"mdcalc_rating": [], "guidelines": [], "teaching": [], "videos": [], "interests": [], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"type": "radio", "label_en": "Cytogenetic group", "default": 0, "conditionality": "", "show_points": true, "tips_en": "", "optional": false, "options": [{"label": "Very good: del(11q) or -Y", "value": 0}, {"label": "Good: normal karyotype, del(20q), del(5q), del(12p), or double including del(5q)", "value": 1}, {"label": "Intermediate: +8, del(7q), i(17q), +19, or any other single or double independent clone", "value": 2}, {"label": "Poor: -7, inv(3)/t(3q)/del(3q), double including -7/del(7q), or complex (3 abnormalities)", "value": 3}, {"label": "Very poor: complex >3 abnormalities", "value": 4}], "name": "cyto"}, {"type": "radio", "label_en": "Medullary blasts, %", "default": 0, "conditionality": "", "show_points": true, "tips_en": "", "optional": false, "options": [{"label": "\u22642", "value": 0}, {"label": ">2 to <5", "value": 1}, {"label": "5 to 10", "value": 2}, {"label": ">10", "value": 3}], "name": "med"}, {"type": "radio", "label_en": "Hemoglobin, g/dL (g/L)", "default": 0, "conditionality": "", "show_points": true, "tips_en": "", "optional": false, "options": [{"label": "\u226510 (\u2265100)", "value": 0}, {"label": "8 to <10 (80 to <100)", "value": 1}, {"label": "<8 (<80)", "value": 1.5}], "name": "hemo"}, {"type": "radio", "label_en": "Platelets, \u00d710\u00b3/\u00b5L (10\u2079/L)", "default": 0, "conditionality": "", "show_points": true, "tips_en": "", "optional": false, "options": [{"label": "\u2265100", "value": 0}, {"label": "50 to <100", "value": 0.5}, {"label": "<50", "value": 1}], "name": "plat"}, {"type": "radio", "label_en": "<calculator id='19'>ANC</calculator>, \u00d710\u00b3/\u00b5L (10\u2079/L)", "default": 0, "conditionality": "", "show_points": true, "tips_en": "", "optional": false, "options": [{"label": "\u22650.8", "value": 0}, {"label": "<0.8", "value": 0.5}], "name": "anc"}], "md5": "", "related_calcs": [{"calcId": "3906", "short_title_en": "EUTOS Score", "slug": "eutos-score-for-chronic-myelogenous-leukemia-cml"}, {"calcId": "2143", "short_title_en": "Sokal Score", "slug": "sokal-index-chronic-myelogenous-leukemia-cml"}, {"calcId": "3929", "short_title_en": "Asymptomatic Myeloma Prognosis", "slug": "asymptomatic-myeloma-prognosis"}]}